Copenhagen, Denmark

Ida Nymann Petersen

This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignees: Københavns Universitet, Rigshospitalet. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ida Nymann Petersen. Retrieved from https://idiyas.com/inventor/ida-nymann-petersen

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 1 

% Patents Active = 100.0

 

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Ida Nymann Petersen: Inventor in Molecular Imaging

Introduction

Ida Nymann Petersen is an inventor associated with Copenhagen, Denmark. Her patent work concerns tetrazine compounds designed for pretargeted in vivo imaging.

Latest Patents

Petersen is associated with one patent, “Tetrazine Compounds for In Vivo Imaging.” The invention describes novel tetrazine compounds for use in pretargeted imaging. These compounds can participate in click-chemistry reactions that join a targeting molecule with a reporter molecule. The patent also describes precursors to the compounds.

Career Highlights

Petersen’s listed institutional affiliations include Rigshospitalet and the University of Copenhagen (Københavns Universitet). Her work connects molecular chemistry with imaging applications.

Collaborations

Her listed collaborators include Matthias Manfred Herth and Jesper Langgard Kristensen.

Conclusion

Ida Nymann Petersen’s patent activity highlights the potential of tetrazine-based click chemistry for linking targeting and reporter molecules in pretargeted in vivo imaging, with 1 patent associated with her.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…